Daily Telegraph (Sydney, Australia) – Apr. 26, 2006
DRUG developer Neuren Pharmaceuticals has jointly filed a patent with the US Army for its brain injury treatment.
Trials found the company’s drug NNZ-2566 significantly reduced non-convulsive seizures which can follow traumatic brain wounds.
The next phase of trials will begin in Melbourne, Auckland and at US field hospitals next year.
Two million people worldwide suffer serious brain injuries each year — and Neuren is expected to tell the Australian Stock Exchange of the joint patent today.
Neuren’s shares last traded at 53.5c.
Source : http://www.therapeuticsdaily.com/news/article.cfm?contentValue=874065&contentType=sentryarticle&channelID=30